@entity715 is responsible for most acute manifestations of @entity453 , including @entity1459 and non-Q-wave @entity583 ( @entity583 ). Antiplatelet therapy plays a major role in reducing the risk of ischaemic events in such @entity1 . Since @entity556 generation is key in the pathogenesis of @entity715 , recent studies have focussed on @entity556 inhibition in the management of acute ischaemia. Heparin is the most widely used anticoagulant for acute management of @entity715 and is the treatment of choice in the prevention and treatment of @entity1211 . Heparin given in therapeutic doses intravenously has been shown to be more effective than @entity117 at reducing the risk of @entity204 or @entity583 in @entity1 with @entity1459 . Low-molecular-weight heparins (LMWHs) have improved pharmacologic and pharmacokinetic properties over standard heparin that may result in greater efficiency and safety. LMWH may be given in fixed doses subcutaneously without monitoring, resulting in greater clinical utility and cost-effectiveness compared with standard heparin. A number of LMWHs- @entity16960 , @entity2120 and nadroparin-have been evaluated in @entity1459 . In a small open trial, @entity11270 reduced the risk of ischaemic outcomes compared with @entity117 alone or a combination of @entity117 and standard heparin. @entity16960 has been evaluated in two large clinical trials in the management of @entity1459 . The low-Molecular-Weight Heparin (Fragmin) During Instability in @entity453 (FRISC) trial showed that @entity16960 resulted in a 63% reduction in risk of @entity204 or acute @entity583 compared with @entity117 alone. The Fragmin in Unstable @entity453 (FRIC) trial showed that @entity16960 was as effective as intravenous heparin. @entity2120 resulted in a statistically significant 16% reduction in the combined outcome of @entity204 , @entity583 and recurrence of @entity951 in comparison with standard heparin in the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial. There is accumulating evidence that LMWHs are safe and effective alternatives to standard heparin in unstable @entity453 and that they offer practical and therapeutic advantages.

Low-molecular-weight heparins and XXXX --current perspectives.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI'] @entity556 :: ('2147', 'Gene') :: ['thrombin'] @entity16960 :: ('MESH:D017985', 'Chemical') :: ['Dalteparin', 'dalteparin'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity11270 :: ('MESH:D017762', 'Chemical') :: ['nadroparin'] @entity2120 :: ('MESH:D017984', 'Chemical') :: ['enoxaparin', 'Enoxaparin'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity951 :: ('MESH:D000787', 'Disease') :: ['angina'] @entity453 :: ('MESH:D003324', 'Disease') :: ['Coronary Artery Disease', 'coronary artery disease'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'Thrombosis'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1459 :: (MESH:D000789,Disease) :: ['unstable angina']
